


## dBET57

<b>Cat. No.:</b>	HY-123844
<b>CAS No.:</b>	1883863-52-2
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>31</sub> ClN <sub>8</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	699.18
<b>Target:</b>	PROTAC; Epigenetic Reader Domain
<b>Pathway:</b>	PROTAC; Epigenetics
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 250 mg/mL (357.56 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.4302 mL	7.1512 mL	14.3025 mL
		<b>5 mM</b>		0.2860 mL	1.4302 mL	2.8605 mL
<b>10 mM</b>		0.1430 mL	0.7151 mL	1.4302 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.97 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	dBET57 is a potent and selective degrader of BRD4 <sub>BD1</sub> based on the PROTAC technology. dBET57 mediates recruitment to the CRL4 <sup>CRBN</sup> E3 ubiquitin ligase, with a DC <sub>50/5h</sub> of 500 nM for BRD4 <sub>BD1</sub> , and is inactive on BRD4 <sub>BD2</sub> <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	BRD4 (BD1) 500 nM (DC50)

### REFERENCES

[1]. Nowak RP, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol. 2018 Jul;14(7):706-714.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA